Vertex and NHS England Set Date For Next Round Of Orkambi Pricing Talks
Executive Summary
Vertex and NHS England are to resume talks next week over pricing of cystic fibrosis drug Orkambi.
You may also be interested in...
Pressure Rises On Vertex and NHS England To Reach Orkambi Deal As Parliamentary Scrutiny Increases
Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.
Vertex Commits To Novel Reimbursement Plan For Orkambi In UK, Despite Setback
Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.